Evaluation of extrusion/spheronisation, layering and compaction for the preparation of an oral, multi-particulate formulation of viable, hIL-10 producing Lactococcus lactis

被引:14
作者
Huyghebaert, N
Vermeire, A
Neirynck, S
Steidler, L
Remaut, E
Remon, JP
机构
[1] Univ Ghent, Fac Pharmaceut Sci, Pharmaceut Technol Lab, B-9000 Ghent, Belgium
[2] Flanders Interuniv Inst Biotechnol VIB, DMBR, Ghent, Zwijnaarde, Belgium
[3] Natl Univ Ireland Univ Coll Cork, Alimentary Pharmabiot Ctr, Cork, Ireland
关键词
extrusion/spheronisation; layering; compaction; viability; L; lactis; recombinant;
D O I
10.1016/j.ejpb.2004.09.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Three formulation techniques were compared in order to develop a multi-particulate formulation of viable, interleukin-10 producing Lactococcus lactis Thy12. First, freeze-dried L. lactis was compacted into mini-tablets. Next, liquid L. lactis culture was used as the granulation fluid for the production of pellets by extrusion/spheronisation. Finally, liquid L. lactis culture was layered on inert pellets as an alternative technique for the production of pellets. L. lactis viability and interleukin-10 production was evaluated. Viability dropped to 15.7% after compaction of freeze-dried L. lactis and to 1.0% after pelletisation of liquid L. lactis by extrusion/spheronisation. The viability in the mini-tablets and pellets stored for 1 week at RT and 10% RH was reduced to 23 and 0.5% of initial viability, respectively. Storage for 1 week at RT and 60% RH resulted in complete loss of viability. Layering of L. lactis on inert pellets resulted in low viability (4.86%), but 1 week after storage at RT and 10% RH. 68% of initial viability was maintained. Increasing product temperature and cell density of L. lactis in the layering suspension did not significantly change viability after layering and storage. Interleukin-10 production capacity of L. lactis Thy12 was maintained after layering. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:9 / 15
页数:7
相关论文
共 23 条
[11]  
Maa YF, 1997, BIOTECHNOL BIOENG, V53, P560, DOI 10.1002/(SICI)1097-0290(19970320)53:6<560::AID-BIT3>3.0.CO
[12]  
2-K
[13]  
MAGGI L, 1994, EUR J PHARM BIOPHARM, V40, P176
[14]   Technological and biological evaluation of tablets containing different strains of lactobacilli for vaginal administration [J].
Maggi, L ;
Mastromarino, P ;
Macchia, S ;
Brigidi, P ;
Pirovano, F ;
Matteuzzi, D ;
Conte, U .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (03) :389-395
[15]   Optimization of a formulation containing viable lactic acid bacteria [J].
Stadler, M ;
Viernstein, H .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2003, 256 (1-2) :117-122
[16]   Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine [J].
Steidler, L ;
Robinson, K ;
Chamberlain, L ;
Schofield, KM ;
Remaut, E ;
Le Page, RWF ;
Wells, JM .
INFECTION AND IMMUNITY, 1998, 66 (07) :3183-3189
[17]   Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10 [J].
Steidler, L ;
Neirynck, S ;
Huyghebaert, N ;
Snoeck, V ;
Vermeire, A ;
Goddeeris, B ;
Cox, E ;
Remon, JP ;
Remaut, E .
NATURE BIOTECHNOLOGY, 2003, 21 (07) :785-789
[18]   Treatment of murine colitis by Lactococcus lactis secreting interleukin-10 [J].
Steidler, L ;
Hans, W ;
Schotte, L ;
Neirynck, S ;
Obermeier, F ;
Falk, W ;
Fiers, W ;
Remaut, E .
SCIENCE, 2000, 289 (5483) :1352-1355
[19]   Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γ [J].
Tilg, H ;
van Montfrans, C ;
van den Ende, A ;
Kaser, A ;
van Deventer, SJH ;
Schreiber, S ;
Gregor, M ;
Ludwiczek, O ;
Rutgeerts, P ;
Gasche, C ;
Koningsberger, JC ;
Abreu, L ;
Kuhn, I ;
Cohard, M ;
LeBeaut, A ;
Grint, P ;
Weiss, G .
GUT, 2002, 50 (02) :191-195
[20]   Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease [J].
vanDeventer, SJH ;
Elson, CO ;
Fedorak, RN .
GASTROENTEROLOGY, 1997, 113 (02) :383-389